Evidence for a lipofibroblast-to-Cthrc1+myofibroblast reversible switch during the development and resolution of lung fibrosis in young mice
Authors:
Open Access
- 10 October 2024
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (2) , 2300482
Abstract
Background: Fibrosis is often associated with aberrant repair mechanisms that ultimately lead to organ failure. In the lung, idiopathic pulmonary fibrosis (IPF) is a fatal form of interstitial lung disease for which there is currently no curative therapy. From the cell biology point of view, the cell of origin and eventual fate of activated myofibroblasts (aMYFs) have taken centre stage, as these cells are believed to drive structural remodelling and lung function impairment. While aMYFs are now widely believed to originate from alveolar fibroblasts, the heterogeneity and ultimate fate of aMYFs during fibrosis resolution remain elusive. We have shown previously that aMYF dedifferentiation and acquisition of a lipofibroblast (LIF)-like phenotype represent a route of fibrosis resolution.Methods: In this study, we combined genetic lineage tracing and single-cell transcriptomics in mice, and data mining of human IPF datasets to decipher the heterogeneity of aMYFs and investigate differentiation trajectories during fibrosis resolution. Furthermore, organoid cultures were utilised as a functional readout for the alveolar mesenchymal niche activity during various phases of injury and repair in mice.Results: Our data demonstrate that aMYFs consist of four subclusters displaying unique pro-alveologenicversuspro-fibrotic profiles. Alveolar fibroblasts displaying a high LIF-like signature largely constitute both the origin and fate of aMYFs during fibrogenesis and resolution, respectively. The heterogeneity of aMYFs is conserved in humans and a significant proportion of human aMYFs displays a high LIF signature.Conclusion: Our work identifies a subcluster of aMYFs that is potentially relevant for future management of IPF.Keywords
Funding Information
- Uniklinikum Giessen und Marburg (FOKOOPV)
- National Institute of Dental and Craniofacial Research (R01DE031044)
- National Eye Institute (5R01EY026202)
- Agence Nationale de la Recherche (ANR-22-CE17-0046-01 MIR-ASO, ANR-PRCI-18-CE92-0009-01 FIBROMIR)
- Deutsche Forschungsgemeinschaft (BE4443/1-1, BE4443/18-1, BE4443/4-1, BE4443/6-1, EL 931/4-1, EL 931/5-1, KFO309 284237345 P7, KFO309 P2/8/Z01, SFB CRC1213 268555672 project A04, SFB CRC1213 268555672 projects A02 and A04, SFB TR84 B9, SFB1021 C05/Z02)
This publication has 32 references indexed in Scilit:
- Alveolar epithelial disintegrity in pulmonary fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2016
- The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary FibrosisPharmacological Reviews, 2015
- The Lung Alveolar Lipofibroblast: An Evolutionary Strategy Against Neonatal Hyperoxic Lung InjuryAntioxidants & Redox Signaling, 2014
- Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosisEuropean Respiratory Review, 2012
- Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGF 1-induced fibroblast differentiation into myofibroblastsThorax, 2010
- The MyofibroblastThe American Journal of Pathology, 2007
- Mechanism of nicotine-induced pulmonary fibroblast transdifferentiationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2005
- Hyperoxia Augments Pulmonary Lipofibroblast-to-Myofibroblast TransdifferentiationCell Biochemistry and Biophysics, 2003
- Simple method of estimating severity of pulmonary fibrosis on a numerical scale.Journal of Clinical Pathology, 1988